Prime Radiant invests $50 million in Cellares

Prime Radiant Partners, an emerging private equity firm, has committed $50 million to Cellares, a biotechnology company specializing in advanced robotics for cancer treatment production. This substantial investment comes as Cellares gears up for a potential initial public offering scheduled for 2027. The funding will likely accelerate Cellares' development and scaling of its innovative manufacturing processes, aiming to revolutionize the mass production of life-saving therapies. The investment highlights growing confidence in the intersection of biotechnology and advanced automation, positioning Cellares for significant growth.